This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
THE WOODLANDS, Texas,
June 24, 2013 /PRNewswire/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, delivered two oral and two poster presentations on LX4211 at the 73
rd Scientific Sessions of the American Diabetes Association (ADA) in
June 23, 2013.
Pablo Lapuerta, M.D., Lexicon's executive vice president, clinical development and chief medical officer, delivered an oral presentation titled
"LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, Reduces Blood Pressure in Patients with Type 2 Diabetes." This presentation highlighted the reductions in blood pressure by LX4211 for subgroups with varying blood pressures at baseline in a 12-week dose-ranging Phase 2b study of 299 patients with type 2 diabetes. Patients with high baseline systolic blood pressure (
>130 mmHg) dosed with LX4211 experienced an average of 14 mmHg reduction in systolic blood pressure when compared to placebo (p=0.002). In contrast, patients with normal systolic blood pressure at baseline (<130 mmHg) experienced an average of 1 mmHg reduction (p=0.6). Systolic blood pressure readings below 100 mmHg, as well as orthostatic systolic blood pressure changes (changes due to a shift in position such as seated-to-standing and supine-to-standing), were no different between patients treated with LX4211 and those on placebo.
"This new analysis of data from the trial shows that LX4211 lowers blood pressure to a greater extent in those patients who are in the greatest need of treatment, that is, those patients with hypertension," said Dr. Lapuerta. "Furthermore, patients with normal blood pressure showed little or no change on LX4211 treatment, a promising finding in regard to future development of LX4211."
Brian Zambrowicz, Ph.D., Lexicon's executive vice president and chief scientific officer, delivered an oral presentation titled
"LX4211, a Dual SGLT1/SGLT2 Inhibitor, Decreases Body Weight and Triglycerides in Patients with Type 2 Diabetes Mellitus and Elevated Baseline Values." This presentation highlighted the reductions in body weight and triglycerides by LX4211 for subgroups with varying body mass indexes (BMI) and triglyceride levels at baseline in the same Phase 2b study. Patients with baseline BMI
>30 treated with 200 mg once-daily, 200 mg twice-daily and 400 mg once-daily treatment all experienced greater average body weight reductions than placebo (p<0.001). Patients with high baseline triglycerides, between 200 and 500 mg/dL, experienced reductions with LX4211 treatment that were significantly larger than those experienced by patients with baseline triglycerides lower than 200 mg/dL in three of the four LX4211 doses tested.
All presentations will be available for download from Lexicon's corporate website
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit
Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, characterizations of the results of and projected timing of clinical trials of LX4211, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.